NLM NIDDK Livertox Database

Livertox

DRUG RECORD

 

EPROSARTAN

 

Introduction

Eprosartan is an angiotensin II receptor blocker used in the therapy of hypertension.  Eprosartan is associated with a low rate of transient serum aminotransferase elevations but has yet to be linked to instances of acute liver injury.

 

Background

Eprosartan is an angiotensin II receptor blocker (ARB) used alone or in combination with other agents for therapy of hypertension.  Eprosartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II which accounts for its potent antihypertensive activity.  Eprosartan was approved for use in the United States in 1997 and is available in 400 and 600 mg tablets under the trade name Teveten.  The typical dose of eprosartan in adults in 400 to 800 mg daily in one or two divided doses, and it is used long term.  Eprosartan is also available in fixed combinations with hydrochlorothiazide (Teveten HCT).  Side effects are uncommon but include headache, dizziness, fatigue, cough and gastrointestinal upset.

 

Hepatotoxicity

Eprosartan has been associated with a low rate of serum aminotransferase elevations (<2%) that in controlled trials was no higher than with placebo therapy.  These elevations were transient and rarely required dose modification.  No specific instances of clinically apparent acute liver injury have been reported in association with eprosartan therapy, but like other ARBs may be associated with rare instances of symptomatic hepatotoxicity.  With most ARBs, onset of liver injury is within 2 to 16 weeks of starting therapy and the serum enzyme pattern is typically hepatocellular with an acute hepatitis-like clinical syndrome.  In some instances, cholestasis has developed which can be prolonged and relapsing, but ARB therapy has not been associated with vanishing bile duct syndrome or chronic liver injury.  Immunoallergic manifestations (rash, fever, eosinophilia) are not common, nor is autoantibody formation.

 

Mechanism of Injury

The cause of the minor serum aminotransferase elevations with eprosartan is not known.  Eprosartan is metabolized in the liver to a glucuronide which is excreted in the urine.  Eprosartan does not appear to be metabolized by the cytochrome P450 system and has minimal drug-drug interactions.

 

Outcome and Management

The instances of acute liver injury reported with ARB use have been self limited and have not resulted in acute liver failure or chronic liver injury.  While corticosteroids have been used in cases of severe cholestasis due to ARBs, their efficacy has not been shown and their use is best avoided.  Patients with eprosartan induced liver injury should probably avoid use of other ARBs, although cross sensitivity to liver injury among the members of this class of agents has not been shown.

[For references, see introductory section on angiotensin II receptor blockers.]

 

Drug Class:  Angiotensin II Receptor Antagonists

 

Other drugs in the Class:  Candesartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan

 

Top of page

 

REPRESENTATIVE TRADE NAMES
Eprosartan – Teveten®

 

DRUG CLASS
Angiotensin II Receptor Antagonists

 

COMPLETE LABELING

FDA product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page

DRUG	CAS REGISTRY NUMBER	MOLECULAR FORMULA	STRUCTURE
Eprosartan	133040-01-4	C23-H24-N2-O4-S

Top of page

 

1. Recent References on Eprosartan

2. Trials on Eprosartan

3. TOXLINE Citations on Eprosartan

Top of page